Chronic psychosis, maintenance therapy after stabilisation with oral haloperidol
Forms and strengths, route of administration
50 mg in 1 ml ampoule (50 mg/ml) for IM injection DO NOT ADMINISTER BY IV INJECTION.
Dosage and duration
Adult: one injection every 3 to 4 weeks
The initial dose of haloperidol decanoate corresponds to approximately 10 times the daily dose of oral haloperidol.
Daily dose oral haloperidol
Monthly dose haloperidol decanoate IM
50 mg solution haloperidol decanoate IM
2.5 mg
25mg
½amp
5 mg
50mg
1amp
10 mg
100 mg
2amp
15 mg
150 mg
3amp
Contra-indications,adverse effects, precautions
Do not administer to patients with cardiac disorders (cardiac failure, recent myocardial infarction, conduction disorders, bradycardia, etc.), dementia (e.g. Alzheimer's disease), Parkinson's disease and history of neuroleptic malignant syndrome.
Administer with caution and carefully monitor use in older patients and patients with hypokalaemia, hypotension, hyperthyroidism, renal or hepatic impairment, history of seizures.
May cause: drowsiness (caution when driving/operating machinery), extrapyramidal syndrome, early or tardivedy skinesia, constipation, dry mouth, sexual dysfunction, QT-prolongation, ventricular arrhythmia, orthostatic hypotension.
In case of extrapyramidal symptoms, try reducing the dose of haloperidol decanoate or, if the extrapyramidal symptoms are severe, add biperiden or trihexyphenidyl.
Avoid or monitor combination with:
fluoxetine, paroxetine, sertraline, promethazine, ritonavir(increased plasma concentrations of haloperidol);
carbamazepine, rifampicin, phenobarbital, phenytoin (decreased plasma concentrations of haloperidol);
drugs that prolong the QT interval(amiodarone, chloroquine, erythromycin, fluconazole, mefloquine, pentamidine, quinine,etc.).
Avoid alcohol during treatment (increased risk of adverse effects).
Avoid in women of childbearing age or offer effective contraception.